SignalFDA/Bio

Abbisko Therapeutics Announces Positive Preliminary Phase 2 Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia

Positive Phase 2 results for Lavengratinib in achondroplasia drive biotech catalyst.

What changed

Positive Phase 2 results for Lavengratinib in achondroplasia drive biotech catalyst.

Why it matters

Positive Phase 2 results for Lavengratinib in achondroplasia drive biotech catalyst. — impact context not separately stored; see What changed.

Sources